TIGIT的生物学作用及其在膀胱癌中应用的研究进展

doi:10.3969/j.issn.1006-5725.2024.12.025

Abstract

Abstract:

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain （TIGIT） is a transmembrane glycoprotein expressed on the surface of immune cells. TIGIT expression is up-regulated in bladder cancer and will have an important impact on bladder cancer development and poor prognosis. Immunotherapy that blocks TIGIT signaling is expected to improve the prognosis of bladder cancer. With further research， TIGIT is likely to become a target for bladder cancer diagnosis and treatment. This article reviews the structure， immunomodulatory effect and the research progress of TIGIT in bladder cancer.

Key words: TIGIT, bladder cancer, CD155, immuno-inhibitory receptor, immunotherapy

CLC Number:

R737.14

Yawei ZHANG,Hongjin SHI,Shi FU,Jiansong WANG,Haifeng WANG. Research progress in biological role of TIGIT and its application in bladder cancer[J]. The Journal of Practical Medicine, 2024, 40(12): 1762-1766.

References 41

1	ATTALLA K， FARKAS A M， ANASTOS H， et al. TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer ［J］. Urol Oncol， 2022， 40（9）： 403-406. doi:10.1016/j.urolonc.2020.06.007 doi: 10.1016/j.urolonc.2020.06.007
2	WEI Y Y， FAN J， SHAN M X， et al. TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection ［J］. Am J Transl Res， 2022， 14（2）： 942-954.
3	PATEL A J， MIDDLETON G W. TIGIT-based immunotherapeutics in lung cancer ［J］. Immunother Adv， 2023， 3（1）： ltad009. doi:10.1093/immadv/ltad009 doi: 10.1093/immadv/ltad009
4	CHIU D K， YUEN V W， CHEU J W， et al. Hepatocellular Carcinoma Cells Up-regulate PVRL1， Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice ［J］. Gastroenterology， 2020， 159（2）： 609-623. doi:10.1053/j.gastro.2020.03.074 doi: 10.1053/j.gastro.2020.03.074
5	LEE J B， HA S J， KIM H R. Clinical Insights Into Novel Immune Checkpoint Inhibitors ［J］. Front Pharmacol， 2021， 12：681320. doi:10.3389/fphar.2021.681320 doi: 10.3389/fphar.2021.681320
6	KAITO Y， HIRANO M， FUTAMI M， et al. CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia ［J］. Oncol Lett， 2022， 23（2）： 51. doi:10.3892/ol.2021.13169 doi: 10.3892/ol.2021.13169
7	MATSUO T， IGUCHI-MANAKA A， SHIBUYA A， et al. CD155 mutation （Ala67Thr） increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT ［J］. Cancer Sci， 2022， 113（11）： 4001-4004. doi:10.1111/cas.15526 doi: 10.1111/cas.15526
8	YOSHIKAWA K， ISHIDA M， YANAI H， et al. Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients ［J］. PLoS One， 2021， 16（6）： e0253176. doi:10.1371/journal.pone.0253176 doi: 10.1371/journal.pone.0253176
9	ZHAN M， ZHANG Z， ZHAO X， et al. CD155 in tumor progression and targeted therapy ［J］. Cancer Lett， 2022， 545：215830. doi:10.1016/j.canlet.2022.215830 doi: 10.1016/j.canlet.2022.215830
10	HARJUNPÄÄ H， GUILLEREY C. TIGIT as an emerging immune checkpoint ［J］. Clin Exp Immunol， 2020， 200（2）： 108-119. doi:10.1111/cei.13407 doi: 10.1111/cei.13407
11	O'DONNELL J S， MADORE J， LI X Y， et al. Tumor intrinsic and extrinsic immune functions of CD155 ［J］. Semin Cancer Biol， 2020， 65：189-196. doi:10.1016/j.semcancer.2019.11.013 doi: 10.1016/j.semcancer.2019.11.013
12	马莉，刘红刚. 脊髓灰质炎病毒受体的生物学特性及其在肿瘤免疫中的研究进展［J］. 中日友好医院学报， 2021， 35（6）： 350-352. doi:10.3969/j.issn.1001-0025.2021.06.008 doi: 10.3969/j.issn.1001-0025.2021.06.008
13	SANCHEZ-CORREA B， VALHONDO I， HASSOUNEH F， et al. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis： Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy ［J］. Cancers （Basel）， 2019， 11（6）： 877. doi:10.3390/cancers11060877 doi: 10.3390/cancers11060877
14	ZENG T， CAO Y， JIN T， et al. The CD112R/CD112 axis： a breakthrough in cancer immunotherapy ［J］. J Exp Clin Cancer Res， 2021， 40（1）： 285. doi:10.1186/s13046-021-02053-y doi: 10.1186/s13046-021-02053-y
15	FRITSCH E F， BURKHARDT U E， HACOHEN N， et al. Personal Neoantigen Cancer Vaccines： A Road Not Fully Paved ［J］. Cancer Immunol Res， 2020， 8（12）： 1465-1469. doi:10.1158/2326-6066.cir-20-0526 doi: 10.1158/2326-6066.cir-20-0526
16	RECHES A， OPHIR Y， STEIN N， et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity ［J］. J Immunother Cancer， 2020， 8（1）： e000266. doi:10.1136/jitc-2019-000266 doi: 10.1136/jitc-2019-000266
17	LIU L， YOU X， HAN S， et al. CD155/TIGIT， a novel immune checkpoint in human cancers （Review）［J］. Oncol Rep， 2021， 45（3）： 835-845. doi:10.3892/or.2021.7943 doi: 10.3892/or.2021.7943
18	LOZANO E， MENA M P， DÍAZ T， et al. Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma ［J］. Clin Cancer Res， 2020， 26（17）： 4688-4698. doi:10.1158/1078-0432.ccr-19-3673 doi: 10.1158/1078-0432.ccr-19-3673
19	SOLOMON B L， GARRIDO-LAGUNA I. TIGIT： a novel immunotherapy target moving from bench to bedside ［J］. Cancer Immunol Immunother， 2018， 67（11）： 1659-1667. doi:10.1007/s00262-018-2246-5 doi: 10.1007/s00262-018-2246-5
20	王尧，巴宏军，柳子川，等. 膀胱癌免疫基因组学分型及其临床意义［J］. 实用医学杂志， 2020， 36（11）： 1452-1456. doi:10.3969/j.issn.1006-5725.2020.11.009 doi: 10.3969/j.issn.1006-5725.2020.11.009
21	LIN F， HU X， ZHANG Y， et al. Upregulated TIGIT（+） and Helios（+） regulatory T cell levels in bronchoalveolar lavage fluid of NSCLC patients ［J］. Mol Immunol， 2022， 147： 40-49. doi:10.1016/j.molimm.2022.04.005 doi: 10.1016/j.molimm.2022.04.005
22	FOURCADE J， SUN Z， CHAUVIN J M， et al. CD226 opposes TIGIT to disrupt Tregs in melanoma ［J］. JCI Insight， 2018， 3（14）： e121157. doi:10.1172/jci.insight.121157 doi: 10.1172/jci.insight.121157
23	MA X， ZHU H， CHENG L， et al. Targeting FGL2 in glioma immunosuppression and malignant progression ［J］. Front Oncol， 2022， 12：1004700. doi:10.3389/fonc.2022.1004700 doi: 10.3389/fonc.2022.1004700
24	FATHI M， PUSTOKHINA I， KUZNETSOV S V， et al. T-cell immunoglobulin and ITIM domain， as a potential immune checkpoint target for immunotherapy of colorectal cancer ［J］. IUBMB Life， 2021， 73（5）： 726-738. doi:10.1002/iub.2461 doi: 10.1002/iub.2461
25	JIANG V C， HAO D， JAIN P， et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma ［J］. Mol Cancer， 2022， 21（1）： 185. doi:10.1186/s12943-022-01655-0 doi: 10.1186/s12943-022-01655-0
26	GE Z， PEPPELENBOSCH M P， SPRENGERS D， et al. TIGIT， the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer ［J］. Front Immunol， 2021， 12： 699895. doi:10.3389/fimmu.2021.699895 doi: 10.3389/fimmu.2021.699895
27	GUR C， IBRAHIM Y， ISAACSON B， et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack ［J］. Immunity， 2015， 42（2）： 344-355. doi:10.1016/j.immuni.2015.01.010 doi: 10.1016/j.immuni.2015.01.010
28	HONG J， GUO F， LU S Y， et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer ［J］. Gut， 2021， 70（11）： 2123-2137. doi:10.1136/gutjnl-2020-322780 doi: 10.1136/gutjnl-2020-322780
29	SHEN X， FU W， WEI Y， et al. TIGIT-Fc Promotes Antitumor Immunity ［J］. Cancer Immunol Res， 2021， 9（9）： 1088-1097. doi:10.1158/2326-6066.cir-20-0986 doi: 10.1158/2326-6066.cir-20-0986
30	RELIGIONI U， CZERW A， DEPTALA A. Assessment of Pain， Acceptance of Illness， Adaptation to Life， and Strategies of Coping With the Disease， in Patients With Bladder Cancer ［J］. In Vivo， 2021， 35（2）： 1157-1161. doi:10.21873/invivo.12363 doi: 10.21873/invivo.12363
31	WU K， ZENG J， SHI X， et al. Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32 ［J］. Front Pharmacol， 2021， 12：801493. doi:10.3389/fphar.2021.801493 doi: 10.3389/fphar.2021.801493
32	LIU Z， ZHOU Q， WANG Z， et al. Intratumoral TIGIT（+） CD8（+） T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer ［J］. J Immunother Cancer， 2020， 8（2）： e000978. doi:10.1136/jitc-2020-000978 doi: 10.1136/jitc-2020-000978
33	AUDENET F， FARKAS A M， ANASTOS H， et al. Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer ［J］. World J Urol， 2018， 36（11）： 1741-1748. doi:10.1007/s00345-018-2359-7 doi: 10.1007/s00345-018-2359-7
34	WU X， LV D， CAI C， et al. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer ［J］. Front Immunol， 2020， 11：590618. doi:10.3389/fimmu.2020.590618 doi: 10.3389/fimmu.2020.590618
35	LI H， LU H， CUI W， et al. A TP53-based immune prognostic model for muscle-invasive bladder cancer ［J］. Aging （Albany NY）， 2020， 13（2）： 1929-1946. doi:10.18632/aging.202150 doi: 10.18632/aging.202150
36	LIU Z， ZENG H， JIN K， et al. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer ［J］. Br J Cancer， 2022， 126（9）： 1310-1317. doi:10.1038/s41416-022-01703-y doi: 10.1038/s41416-022-01703-y
37	HAN H S， JEONG S， KIM H， et al. TOX-expressing terminally exhausted tumor-infiltrating CD8（+） T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer ［J］. Cancer Lett， 2021， 499：137-147. doi:10.1016/j.canlet.2020.11.035 doi: 10.1016/j.canlet.2020.11.035
38	叶强，陈小燕. 免疫检查点抑制剂的内分泌毒性及临床应对策略［J］. 实用医学杂志， 2021， 37（11）： 1382-1386. doi:10.3969/j.issn.1006-5725.2021.11.002 doi: 10.3969/j.issn.1006-5725.2021.11.002
40	ROUSSEAU A， PARISI C， BARLESI F. Anti-TIGIT therapies for solid tumors： a systematic review ［J］. ESMO Open， 2023， 8（2）： 101184. doi:10.1016/j.annonc.2021.11.002 doi: 10.1016/j.annonc.2021.11.002
41	CHEN S， ZHANG N， SHAO J， et al. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer ［J］. J Cancer， 2019， 10（3）： 697-707. doi:10.7150/jca.28494 doi: 10.7150/jca.28494

[1]	Zhicong LIU,Daiyin LIU,Juntian LONG,Chixing CHENG,Jian HUANG. Exosomal lncRNA CIAT1 promotes collective invasion of bladder cancer [J]. The Journal of Practical Medicine, 2025, 41(9): 1299-1308.
[2]	Daiyin LIU,Qiuyan LI,Changhao. CHEN. CircMYCBP2 enhances the formation of lymphovascular invasion of bladder cancer [J]. The Journal of Practical Medicine, 2025, 41(8): 1139-1148.
[3]	Qiang FU,Zhongqi LU,Ying CHANG,Tiefeng JIN,Meihua. ZHANG. Research progress on the antitumor effects of immune checkpoint inhibitors [J]. The Journal of Practical Medicine, 2025, 41(2): 288-293.
[4]	Zegong HU,Yan BAI. Research advances in allergen-specific immunotherapy [J]. The Journal of Practical Medicine, 2025, 41(11): 1760-1766.
[5]	Xufeng YU,Meimian HUA,Shuxiong ZENG,Wei HE,Ziwei WANG,Qing CHEN,Chen ZHANG,Yue WANG,Yi WANG,Chuanliang. XU. Clinical efficacy comparison of ileal conduit， flap embedding method， and traditional cutaneous ureterostomy in patients with bladder cancer [J]. The Journal of Practical Medicine, 2025, 41(10): 1517-1524.
[6]	Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma [J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.
[7]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[8]	Ziqi DING,Qian. ZHANG. Research progress in T cell exhaustion and its relationship with respiratory diseases [J]. The Journal of Practical Medicine, 2024, 40(13): 1895-1900.
[9]	Xizhi WEN,Xiaoshi. ZHANG. Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma [J]. The Journal of Practical Medicine, 2024, 40(10): 1331-1337.
[10]	WU Kaiyi, LÜ Xuedong, HE Haiyan, CHEN Jinliang. . Progress in the application of cryoablation combined with immunotherapy in the treatment of NSCLC [J]. The Journal of Practical Medicine, 2023, 39(8): 1058-1062.
[11]	ZHANG Xijie, LI Xin, ZHOU Wence.. Research progress of combined immunotherapy for metastatic pancreas cancer [J]. The Journal of Practical Medicine, 2023, 39(6): 655-659.
[12]	CHEN Fukun, LV Juan, DENG Zhiyong. Effect of chimeric antigen receptor gene⁃modified T⁃cell immunotherapy for lung cancer：A systematic review [J]. The Journal of Practical Medicine, 2023, 39(5): 538-543.
[13]	WU Yang, LU Hanjie, SHUI Huifeng.. The efficacy and safety of anlotinib plus PD⁃1 blockades in patients with advanced non⁃small cell lung can⁃ cer previously treated with immunotherapy [J]. The Journal of Practical Medicine, 2023, 39(5): 572-578.
[14]	Feng XIAO,Xi′nan JIANG,Lu SHU,Jiaqi SHI,Fangmin CHEN,Yi. MU. Expression of ECM1 gene in bladder cancer and its relationships with clinical pathological features and prognosis [J]. The Journal of Practical Medicine, 2023, 39(20): 2629-2632.
[15]	Xianlan ZHANG,Yufei ZHU,Yunyun ZENG,Zhihao HUANG,Wenchang CEN,Shan. SU. Efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating advanced non-small cell lung cancer [J]. The Journal of Practical Medicine, 2023, 39(16): 2112-2115.

Research progress in biological role of TIGIT and its application in bladder cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 15

Recommended Articles

Metrics

Comments